ClinicalTrials.Veeva

Menu
C

Colorado Springs Neurological Associates | Colorado Springs, CO

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Droxidopa
Lasmiditan
Erenumab
LY573144
Atogepant
Cenobamate
Fycompa
Donanemab
Rimegepant
LY3372993

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 35 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Enrolling
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Al...

Enrolling
Psychosis Associated With Alzheimer's Disease
Drug: Placebo
Drug: KarXT

This study is researching an experimental combination treatment with pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on pa...

Enrolling
Generalized Myasthenia Gravis
Drug: Pozelimab
Drug: Pozelimab + Cemdisiran
Locations recently updated

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 3
Drug: Erenumab Dose 1
Locations recently updated

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years)...

Enrolling
Migraine
Drug: Erenumab Dose 2
Drug: Erenumab Dose 3

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling
Primary Generalized Epilepsy
Drug: Placebo
Drug: Cenobamate

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized...

Enrolling
Relapsing Remitting Multiple Sclerosis
Drug: Placebo
Drug: PIPE-307 Dose B

Trial sponsors

Allergan logo
Lilly logo
Pfizer logo
Amgen logo
M
Celgene logo
Cincinnati Children's Hospital Medical Center logo
C
C
Duke University logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems